Decay and persistence of maternal dengue antibodies among infants in Bangkok.

Abstract. Maternal dengue antibodies are important in determining the optimal age of dengue vaccination, but no study has quantified the heterogeneity of antibody decay and persistence in infants. We used longitudinal regression methods and survival analysis to measure decay and persistence times of serotype-specific neutralizing antibodies in 139 infants in Bangkok. A biphasic decay pattern was found with half-life times of 24-29 days between birth and 3 months and 44-150 days after 3 months. Atypical decay rates were found in 17% of infants for dengue virus-1 and -4. Median persistence times of plaque reduction neutralization tests > 10 ranged from 6 to 9 months. Persistence times for individuals could not be predicted based on antibody values at birth. Vaccination against dengue before 12 months of age would be ineffective if maternal antibodies at plaque reduction neutralization test levels below 80 interfere with vaccine uptake. Projections of average antibody persistence based on values at birth should be avoided in studies on dengue pathogenesis in infants.

[1]  J. Hombach,et al.  WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11-12 May 2009. , 2010, Vaccine.

[2]  Rosanna W. Peeling,et al.  Dengue: a continuing global threat , 2010, Nature Reviews Microbiology.

[3]  B. Guy,et al.  Development of sanofi pasteur tetravalent dengue vaccine , 2010, Human vaccines.

[4]  R. Jarman,et al.  The incidence, characteristics, and presentation of dengue virus infections during infancy. , 2010, The American journal of tropical medicine and hygiene.

[5]  Cameron P Simmons,et al.  Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. , 2009, The Journal of infectious diseases.

[6]  A. Nisalak,et al.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. , 2009, The American journal of tropical medicine and hygiene.

[7]  D. Webster,et al.  Progress towards a dengue vaccine. , 2009, The Lancet. Infectious diseases.

[8]  R. Jarman,et al.  A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.

[9]  J. Lang,et al.  AGE-SPECIFIC PREVALENCE OF DENGUE ANTIBODIES IN BANGKOK INFANTS AND CHILDREN , 2008, The Pediatric infectious disease journal.

[10]  J. Farrar,et al.  Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. , 2007, The Journal of infectious diseases.

[11]  J. Lang,et al.  Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. , 2006, The Journal of infectious diseases.

[12]  E. Harris,et al.  Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. , 2005, The American journal of tropical medicine and hygiene.

[13]  C. Leclerc,et al.  Neonatal adaptive immunity comes of age , 2004, Nature Reviews Immunology.

[14]  S. Yoksan,et al.  Maternally transferred neutralising dengue antibodies in Thai infants: a pilot study , 2003, Annals of tropical paediatrics.

[15]  A. Nisalak,et al.  Transplacentally transferred maternal-infant antibodies to dengue virus. , 2003, The American journal of tropical medicine and hygiene.

[16]  C. Siegrist Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. , 2003, Vaccine.

[17]  Tao Dong,et al.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.

[18]  Donald S Burke,et al.  Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. , 2003, The American journal of tropical medicine and hygiene.

[19]  S. Halstead,et al.  Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored , 2002, Emerging infectious diseases.

[20]  Y. Maldonado,et al.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. , 2001, The Journal of infectious diseases.

[21]  C. Siegrist Neonatal and early life vaccinology. , 2001, Vaccine.

[22]  Ting-Hsiang Lin,et al.  Dengue NS1‐specific antibody responses: Isotype distribution and serotyping in patients with dengue fever and dengue hemorrhagic fever , 2000, Journal of medical virology.

[23]  P. Diggle Analysis of Longitudinal Data , 1995 .

[24]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[25]  S. Halstead,et al.  Antibody-enhanced dengue virus infection in primate leukocytes , 1977, Nature.

[26]  A. Nisalak,et al.  A plaque reduction test for dengue virus neutralizing antibodies. , 1967, Journal of immunology.

[27]  S. Halstead,et al.  Neutralization and antibody-dependent enhancement of dengue viruses. , 2003, Advances in virus research.

[28]  A. Nisalak,et al.  A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.